Generics and New Goods in Pharmaceutical Price Indexes
38 Pages Posted: 28 May 2004 Last revised: 29 Jun 2012
Date Written: February 1993
Abstract
We examine the issue of new goods and price indexes for the important and tractable case of generic and branded drugs. By treating generics as entirely distinct goods and "linking them in" to indexes with fixed weights, the standard price indexes fail to reflect the substantial welfare gains to those consumers who, like the FDA, regard generic and branded versions of a drug as being perfect substitutes. We discuss the treatment of heterogenous consumers in constructing aggregate price indexes, and then, using detailed data on wholesale prices of two anti-infective drugs, present calculations of various alternatives to the official indexes. These reflect both heterogeneity of tastes for brandedness, and also the empirically important phenomenon of diffusion of generic drugs into the market following patent expiration. We find very significant differences: for one of the drugs studied, the standard price index rose by 14% over the sample period, while our preferred alternative index fell by 48%.
Suggested Citation: Suggested Citation
Here is the Coronavirus
related research on SSRN
Recommended Papers
-
Household Demand for Broadband Internet Service
By Gregory L. Rosston, Scott Savage, ...
-
Using Pseudo-Panels to Measure Income Mobility in Latin America
By Jose Cuesta, Hugo Opo, ...
-
Fighting City Hall: Entry Deterrence and New Technology Deployment in Local Cable TV Markets
-
Mixed Oligopoly Equilibria When Firms' Objectives are Endogenous
By Philippe De Donder and John E. Roemer
-
Mixed Oligopoly Equilibria When Firms' Objectives are Endogenous
By Philippe De Donder and John E. Roemer
-
Forecast Models of Broadband Diffusion and Other Information Technologies
